Multiparametric liver MRI could refine the way we currently approach testing of therapeutic candidates in preclinical models
- July 3, 2018
- Liver Disease, NAFLD, NASH, LiverMultiScan
Research led by Professor Jonathan Fallowfield, Chair of Translational Liver Research at University of Edinburgh, in collaboration with GlaxoSmithKline, showed that multiparametric MRI can be used to assess liver tissue characteristics in preclinical drug testing for Non-alcoholic Fatty Liver Disease (NAFLD). The method showed good diagnostic accuracy in animal models of liver disease and correlated with gold standard microscopic assessment of liver tissue samples. Non-invasive methods for assessing liver disease is a major obstacle to the drug development process, this feasibility study suggests that multiparametric MRI could refine the way testing of therapeutic candidates could be approached (in preclinical models)
Read the whole manuscript here.